Stock Events

Stock Events

BioAtla 

$0.16
0
+$0.01+6.51% Today

Statistics

Day High
0.16
Day Low
0.15
52W High
-
52W Low
-
Volume
5,734
Avg. Volume
-
Mkt Cap
9.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Next
-0.3
-0.26
-0.23
-0.2
Expected EPS
-0.2
Actual EPS
N/A

Financials

-634.33%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
22MRevenue
-139.55MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCAB.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biotechnology space, focusing on innovative biologic medicines, similar to BioAtla's approach to developing antibody-based therapeutics.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm that develops novel therapeutics, including in oncology, which is a direct competition to BioAtla's cancer-focused therapies.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a global healthcare company that develops cancer drugs and vaccines, competing with BioAtla's development of novel oncology treatments.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including cancer therapies that compete with BioAtla's portfolio.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops drugs for life-threatening illnesses, including cancer, making it a competitor to BioAtla.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical corporation with a broad range of healthcare products, including oncology, directly competing with BioAtla.
Novartis
NVS
Mkt Cap237.61B
Novartis is a healthcare company that focuses on innovative medicines, with a strong emphasis on oncology, competing with BioAtla's cancer therapies.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a leader in research-focused healthcare with a strong portfolio in cancer treatment, making it a competitor to BioAtla.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on oncology, among other areas, competing with BioAtla.

About

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Show more...
CEO
ISIN
US09077B1044

Listings

XNAS
US
BCAB
BOATS
BOATS
BCAB.BOATS

0 Comments

Share your thoughts

FAQ

What is BioAtla stock price today?▼
The current price of BCAB.BOATS is $0.16 USD — it has increased by +6.51% in the past 24 hours. Watch BioAtla stock price performance more closely on the chart.
What is BioAtla stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange BioAtla stocks are traded under the ticker BCAB.BOATS.
What is BioAtla market cap?▼
Today BioAtla has the market capitalization of 9.61M
When is the next BioAtla earnings date?▼
BioAtla is going to release the next earnings report on May 13, 2026.
What were BioAtla earnings last quarter?▼
BCAB.BOATS earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.3 USD resulting in a +8.99% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BioAtla revenue for the last year?▼
BioAtla revenue for the last year amounts to 22M USD.
What is BioAtla net income for the last year?▼
BCAB.BOATS net income for the last year is -139.55M USD.
When did BioAtla complete a stock split?▼
BioAtla has not had any recent stock splits.